Table 1.
Patient demographics and medical characteristics. ALL, acute lymphoblastic leukemia.
| Patient number | Group | CSF AVP (pg/ml) | Age (years) | Ethnicity | Sample collection time | Indications for CSF procedure | Diagnosis/ pathology report |
|---|---|---|---|---|---|---|---|
| 1 | ASD | 32.97 | 6.58 | Asian | 09:30 | Evaluation for metabolic disorder | No abnormality determined |
| 2 | ASD | 11.47 | 6.08 | Caucasian | 10:00 | Maintenance chemotherapy | ALL in remission |
| 3 | ASD | 24.09 | 6.75 | Asian | 07:50 | Evaluation for metabolic disorder | No abnormality determined |
| 4 | ASD | 30.12 | 18.83 | Caucasian | 11:40 | Maintenance chemotherapy | ALL in remission |
| 5 | ASD | 19.77 | 9.92 | Caucasian | 11:16 | Evaluation for autoimmune or degenerative encephalopathies | No abnormality determined |
| 6 | ASD | 12.07 | 5.30 | Asian | 09:40 | Evaluation for metabolic disorder or degenerative encephalopathies | No abnormality determined |
| 7 | ASD | 15.80 | 6.92 | Caucasian | 12:37 | Evaluation for autoimmune or degenerative encephalopathies | Elevated inflammatory markers |
| 8 | Control | 27.45 | 6.33 | Caucasian | 09:40 | Maintenance chemotherapy | ALL in remission |
| 9 | Control | 26.42 | 5.25 | Caucasian | 08:29 | Maintenance chemotherapy | ALL in remission |
| 10 | Control | 40.68 | 7.83 | Caucasian | 08:40 | Maintenance chemotherapy | ALL in remission |
| 11 | Control | 41.41 | 19.50 | Caucasian | 18:26 | Evaluation for meningitis | No abnormality determined |
| 12 | Control | 32.69 | 10.42 | Asian | 08:30 | Induction chemotherapy | Relapsed ALL |
| 13 | Control | 26.81 | 6.42 | Caucasian | 08:40 | Maintenance chemotherapy | ALL in remission |
| 14 | Control | 32.55 | 7.50 | Caucasian | 13:09 | Maintenance chemotherapy | ALL in remission |